Women experience two hormonal crises men never face: monthly progesterone withdrawal that drives PMS, and an abrupt triple hormone collapse in their 50s — estrogen, progesterone, and testosterone all gone within two to three years.
2
Testosterone is often treated as a purely male hormone, but unit-for-unit it runs about ten times higher than estrogen even in women — meaning menopause strips away a woman's dominant hormone along with the others, a fact most clinicians miss.
3
Attia's top clinical pet peeve: doctors who dismiss hormone replacement without reading a single Women's Health Initiative study and tell women to 'just deal with' hot flashes, muscle loss, and bone density decline.
4
Two under-recognized women's health patterns fall through the cracks: post-partum thyroid dysfunction after 3-4 pregnancies (normal TSH, altered T4 conversion), and women's lower cardiovascular disease rate which may trace to menstrual iron loss as a protective mechanism.
Protocols
Concrete recipes — what, when, how much, and why
5 items
Map the full 28-31 day hormone curve to explain and validate PMS symptoms
WhatDraw or show a patient the complete menstrual cycle hormone trajectory — FSH, LH, estradiol, progesterone, and testosterone — highlighting the day 22-28 progesterone drop and its central nervous system effects. Use this to reframe PMS from a psychological complaint to a neuroendocrine event.
WhenAt the first consultation with a female patient reporting mood swings, emotional lability, or 'feeling crazy' around their cycle.
DoseSingle whiteboard session; the map can be revisited as symptoms change or treatment is adjusted.
For whomWomen of reproductive age with PMS or luteal-phase mood disruption who have not received a physiological explanation for their symptoms.
WhyUnderstanding the hormonal mechanism destigmatizes the experience, improves treatment adherence, and opens the door to targeted interventions. Attia's patient had a transformative response simply to being shown the data.
Attia describes sitting in his patient's living room and drawing this out in full detail. The patient's reaction — 'oh my god, I've always thought I was kind of crazy' — reveals how profoundly the absence of this education affects women's self-perception. The mechanism is specific: progesterone has potent neuroactive metabolites (allopregnanolone) that act on GABA receptors; their withdrawal around day 22-28 is pharmacologically similar to benzodiazepine withdrawal for susceptible women.
Mechanism
Progesterone is metabolized to allopregnanolone, a positive GABA-A receptor modulator. The sharp drop in progesterone at the end of the luteal phase acts as a neurological withdrawal event in women with high central sensitivity, producing irritability, anxiety, and emotional lability.
I was sitting down with her in her living room actually drawing this out for her and explaining to her why she has PMS and let's highlight what's happening on about day 22 to 28 which is when you have this drop in progesterone and explaining to her that for some women that central meaning in the in the brain that reduction that withdrawal of progesterone can create emotional lability
Assess peripheral T4-to-T3 conversion in women with post-partum fatigue, not just TSH
WhatIn women who present with persistent low energy after their third or fourth pregnancy, do not stop at TSH. Measure free T3, reverse T3, and T4-to-T3 conversion ratios to detect impaired peripheral thyroid metabolism that standard screening misses.
WhenWhen a female patient reports 'I have not been able to get back to the same energy level since my third or fourth child' and standard TSH returns normal.
For whomWomen who have had three or more pregnancies, present with chronic fatigue or low energy, and have been dismissed after a normal TSH.
WhyMultiple pregnancies appear to alter HPA axis function in a way that disrupts peripheral T4 conversion without affecting TSH feedback. A normal TSH means the pituitary-thyroid axis is intact but says nothing about how the periphery handles T4.
CaveatsAttia acknowledges he has not found strong published literature on this specific pattern; it is an empirical clinical observation. Order tests in context of full clinical picture.
Attia describes these as 'easiest saves' in his practice — patients who have fallen through the cracks of standard care. The consistent pattern: three or four pregnancies, subjective fatigue not matching normal TSH, altered peripheral T4 metabolism found on further testing. Treatment (targeted thyroid support) produces rapid, dramatic improvement. The underlying mechanism is presumed to involve cumulative HPA axis strain from multiple gestations disrupting hypothalamic-pituitary-thyroid signaling downstream of TSH.
you look at them and they have a normal TSH typically but but usually their peripheral metabolism of t4 is is very altered and and these are I think in some ways like kind of the easiest saves like you in a very short period of time you can make a patient feel a hell of a lot better and and they're just there they sort of fall through the cracks
Treat dismissal of menopausal HRT as a knowledge failure requiring active correction
WhatBefore advising any menopausal or perimenopausal patient to forego hormone replacement, read and understand the actual Women's Health Initiative methodology, its limits, and the subsequent analyses. Do not default to 'hormones cause cancer' without understanding what the WHI actually found and didn't find.
WhenAt any clinical encounter where a peri- or post-menopausal woman asks about HRT, or whenever evaluating a patient with hot flashes, bone density decline, or muscle loss attributable to menopause.
For whomClinicians treating peri- and post-menopausal women; patients who have been told to 'just deal with' their symptoms.
WhyAll three sex hormones disappear in two to three years at menopause. The downstream consequences — muscle mass loss, bone density loss, cardiovascular risk changes, cognitive changes — are substantial and preventable. Reflexive HRT refusal based on a misread of WHI data leaves women undertreated.
CaveatsAttia does not outline specific HRT protocols in this episode — this is a framing/attitude protocol, not a dosing protocol.
Attia is unusually emphatic here: it is a 'top 5 pet peeve' when doctors 'completely disregard menopausal, perimenopausal, and post-menopausal symptoms in women' without having read the relevant literature. The specific error is conflating the WHI findings (which used conjugated equine estrogen and synthetic progestins in older women) with blanket hormone risk for all women. The collateral damage of this misreading: women allowed to lose muscle mass, bone density, and cognitive function that could have been preserved.
definitely top 10 pet peeves are maybe top 5 pet peeves are doctors that completely disregard menopausal perimenopausal and post menopausal symptoms and women and who without having ever even read a single study or tried to understand the limits and the methodologies of the Women's Health Initiative come to the conclusion well no woman should ever take hormones and they should just you know deal with their post menopausal hot flashes and eventually you know let them lose their muscle mass and bone density because God forbid hormones cause cancer
Monitor iron levels as a sex-specific cardiovascular risk variable in post-menopausal women
WhatConsider measuring iron status (serum ferritin, serum iron, transferrin saturation) in post-menopausal women as part of cardiovascular risk assessment — particularly in metabolically compromised patients — since the protective iron-reduction effect of menstruation is now absent.
WhenAt menopause or within the first few years after last menstrual period, as part of comprehensive cardiovascular risk workup.
For whomPost-menopausal women, particularly those with metabolic dysfunction or elevated cardiovascular risk.
WhyIron's oxidative stress contribution to cardiovascular disease is documented in men. Women of reproductive age likely benefit from cyclical iron reduction via menstrual blood loss. After menopause, iron accumulates toward male-equivalent levels, potentially erasing a lifetime of cardiovascular protection.
CaveatsAttia explicitly flags this as speculative and not yet rigorously documented. The therapeutic phlebotomy data in men is strongest in metabolically deranged patients; the magnitude of benefit in metabolically healthy women post-menopause is unknown.
The clinical reasoning chain: therapeutic phlebotomy benefits metabolically deranged men (by reducing iron-driven oxidative stress) more than metabolically healthy men. Women during reproductive years mirror this effect involuntarily. After menopause, iron accumulates. If iron oxidative stress is a meaningful driver of cardiovascular risk, post-menopausal iron monitoring and potentially targeted management becomes relevant. Attia flags he would like to see this rigorously studied.
there's pretty interesting data in men that the more metabolically deranged they are the better they do with therapeutic phlebotomy whereas the less metabolically deranged they are the less of an effect they have by giving blood reducing the oxidative stress of iron so it might be the case that somewhere buried within there is this idea that because for a great number of years of a woman's life she is going to have less iron than a man due to her menstrual cycle that may actually offer a protective benefit against heart disease
Study women as women — not as smaller men — in research design and clinical interpretation
WhatWhen interpreting any clinical study, check whether women were adequately represented as subjects and whether findings were analyzed by sex. When treating female patients, do not default to male-derived dosing, reference ranges, or disease presentations.
WhenApplies to research design, clinical trial interpretation, and any treatment protocol derived from studies that underrepresented women.
For whomClinicians, researchers, and patients critically appraising medical evidence.
WhyThe thalidomide-era exclusion of women from research created a decades-long evidence gap. Female physiology — hormone fluctuations, reproductive events, sex-specific disease patterns — cannot be inferred from male data. Diseases like Alzheimer's and cardiovascular disease present differently by sex.
Attia references the Freakonomics podcast discussion of thalidomide's consequences, noting women were taken 'virtually off the table in terms of studying' for a long period. The downstream effect is that many reference ranges, drug doses, and disease risk models are calibrated to male subjects. The resurgence in women-specific epidemiology is positive but incomplete — 'they've been under study just in that regard as well, just looking at the female body versus the male body instead of just assuming they're the same.'
there's a long period of time where it was I think men were predominantly being studied and with subjects of yeah yeah we would just sort of assume that whatever is we see in the men we might see in the women but I think there's been as far as epidemiology goes there's been a resurgence in women's studies and things like that but I do think that there's overall they've been under study just in that regard as well just looking at the female body versus the male body instead of just assuming you know they're they're the same
What's new
Personal practice updates, fresh positions, predictions
6 items
Menopause is a triple hormone collapse — testosterone included
~mid
Most people think of menopause as an estrogen/progesterone event, but testosterone also disappears in women. When you normalize testosterone and estrogen to the same units, testosterone runs about ten times higher than peak estrogen in a premenopausal woman. Losing all three in a two-to-three year window is a seismic physiological event.
Why this matters: The framing that testosterone 'doesn't matter in women' leads clinicians to miss half the hormonal picture when treating menopausal patients.
Background
Testosterone is reported in nanograms per deciliter; estrogen in picograms per milliliter — the different units obscure the true ratio. A woman's free testosterone might be 1 ng/dL while a man's median is about 14-15 ng/dL, but even 1 ng/dL is still roughly ten times the unit-equivalent estrogen level during ovulation.
Attia walks through the unit conversion explicitly: the highest estrogen in a woman's life (outside pregnancy) is the peri-ovulatory spike — yet when you put both hormones in the same units, testosterone is still dominant. This means menopause is not just about losing 'female hormones'; it is about losing the quantitatively dominant steroid as well. The clinical downstream is clear: muscle loss, libido changes, fatigue, and mood changes that are often attributed to estrogen deficiency alone.
when you actually convert the units to the same numbers so when you go from nanograms per deciliter and pika grams per milliliter which they're often reported in different units and you do an apples-to-apples view when you look at a woman's highest estrogen level in her life which i mean outside of pregnancy is during her ovulate or e-cycle the testosterone is about ten times higher than the estrogen
PMS is progesterone withdrawal acting on the brain — not a mood disorder
~early-mid
Around days 22-28 of the menstrual cycle, progesterone drops sharply. For women with a strong central sensitivity to this withdrawal, the result is emotional lability, irritability, and mood disruption — not a psychiatric problem but a predictable neuroendocrine event. Hereditary in pattern.
Why this matters: Framing PMS as a neurological response to hormone withdrawal rather than a personality or mood disorder changes how patients understand themselves and opens treatment pathways.
Background
Attia's patient came to him specifically to control emotional swings across her cycle. Drawing the full hormone curve (FSH, LH, estradiol, progesterone, testosterone) across 28-31 days allowed her to see exactly when symptoms would peak.
Attia sat in his patient's living room and drew the complete 28-31 day hormone trajectory, highlighting day 22-28 when progesterone collapses. The patient's response — 'I've always just thought I was kind of crazy' — illustrates how broadly this is misunderstood even by the women experiencing it. Attia compared it to serotonin deficiency in depression: a physiological reality, not a character flaw. He noted it is hereditary ('your mom went through the same thing, your sister goes through the same thing') and that two practical interventions exist — though he declined to detail them in this episode.
for some women that central meaning in the in the brain that reduction that withdrawal of progesterone can create emotional lability and other things and it's like you're not crazy like that's that's that's like saying like someone who's depressed because they don't have enough serotonin is crazy no I mean it's just everyone has different neurotransmitters and everyone has a different response to hormones
Also said
“I've always just thought I was kind of crazy and I'm just like a moody and I was like no I mean your mom went through the same thing your sister goes through the same thing I mean this is hereditary”— Patient's voice illustrates how pervasive the misunderstanding is — and that the correct frame is biological, not psychological.
Post-partum thyroid dysfunction after 3-4 pregnancies falls through the cracks
~mid-late
Attia observes empirically — though acknowledges he hasn't found it described in the literature — that after three or four pregnancies, women's thyroid function (specifically peripheral T4 metabolism) often does not return to baseline. Standard TSH testing comes back normal, masking the dysfunction. These patients present with persistent low energy and are easily helped once the T4 conversion abnormality is identified.
Why this matters: TSH-only thyroid screening misses this pattern, leaving patients suffering for years after their third or fourth child when the fix is straightforward.
Background
The HPA axis is stressed by multiple pregnancies; Attia has seen this pattern consistently in longevity-seeking patients whose chief complaint is 'I have not been able to get back to the same level of energy since my third or fourth child.'
Attia flags this as one of the 'easiest saves' in his practice — a patient who feels terrible but tests normal on standard panels. When peripheral T4-to-T3 conversion is specifically examined, the dysfunction becomes apparent, and targeted thyroid support produces rapid dramatic improvement. The pattern is not seen after one or two pregnancies, only after three or four — consistent with cumulative HPA axis strain. He explicitly states he has not seen this rigorously documented and would be surprised if it isn't in the literature somewhere.
empirically it is so overwhelming that I would be surprised if it's not described in the literature is there's something about multiple pregnancies and the HPA axis and women so I usually don't see it after a woman has had two kids but usually if a woman has had three or four kids the likelihood that her thyroid bounces back to normal seem is not that high
Also said
“you look at them and they have a normal TSH typically but but usually their peripheral metabolism of t4 is is very altered and and these are I think in some ways like kind of the easiest saves like you in a very short period of time you can make a patient feel a hell of a lot better”— Explains the diagnostic and treatment pattern: TSH-normal but T4-conversion abnormal, rapidly correctable.
Women's lower cardiovascular disease rate may trace to menstrual iron loss
~late
Epidemiologically, women get less heart disease than men even when you control for most risk factors. Attia raises the hypothesis that chronic, cyclical reduction in iron stores via menstruation may reduce oxidative stress in the same way therapeutic phlebotomy helps metabolically deranged men — potentially a structural protective mechanism built into reproductive biology.
Why this matters: If validated, this would be a mechanistic explanation for the sex gap in heart disease risk that goes beyond estrogen, and would have implications for post-menopausal iron monitoring.
Background
Therapeutic phlebotomy data in men shows the intervention helps most in metabolically deranged individuals (by reducing oxidative iron load). Women's monthly blood loss creates a parallel cyclical iron reduction throughout reproductive years.
Attia frames this as speculative but consistent with existing data. He specifically notes the CVD gap persists even when you normalize for ApoB, LDL, inflammation, insulin sensitivity, blood pressure, and smoking — the standard cardiovascular risk factors. After exhausting those, iron levels become the next logical variable. The epidemiologic data is imperfect (he suspects studies haven't rigorously normalized for ApoB), but the directional finding of female CVD protection is robust enough to warrant mechanistic exploration.
it might be the case that somewhere buried within there is this idea that because for a great number of years of a woman's life she is going to have less iron than a man due to her menstrual cycle that may actually offer a protective benefit against heart disease
Two of every three Alzheimer's cases are women — and age alone doesn't explain it
~late
Attia cites the statistic that two-thirds of Alzheimer's patients are women, then questions the standard explanation (women live longer). He does not think the longevity gap explains that large a prevalence ratio and believes the sex-specific risk is under-studied.
Why this matters: If the gap isn't purely age-related, then sex-specific hormonal or biological factors are driving disproportionate Alzheimer's risk in women — a high-priority research question.
Background
Attia is about to record an episode with neurologist Richard Isaacs and flags this as a topic he expects to explore in depth.
The 2/3 figure is particularly striking in context: it cannot be fully explained by longevity because the longevity differential is not large enough to produce that ratio. Attia's concern is also diagnostic: when you're looking at prevalence data by sex, you need to make sure you're not being fooled by differential diagnostic rates — whether women are diagnosed more readily, or whether their symptoms are recognized earlier or later. He explicitly wants to have a rigorous discussion about whether this is a true biological predisposition or a confounded epidemiological signal.
if you look at Alzheimer's disease and you look at the prevalence I think it's two out of every three cases are women and you could probably say that age is a factor in longevity may be a factor and things like that but I think that that needs to be studied more because I have a hard time believing that that is purely an age issue
Thalidomide's legacy: women excluded from clinical research for decades
~late
Thalidomide's birth-defect catastrophe led to a decades-long de facto exclusion of women from clinical trials. Men were the default study subject, with findings assumed to apply to women. This left a massive evidence gap in female physiology that is only now being partially addressed.
Why this matters: The research gap has direct clinical consequences: drug dosing, disease presentation, and response to intervention are all calibrated on male data — and may not translate.
Attia references a Freakonomics podcast episode that covered the thalidomide-driven exclusion. The consequence was that for a long period, women were essentially studied by assumption rather than directly. He acknowledges the epidemiological resurgence in women's studies but notes they remain underrepresented overall — 'instead of just assuming they're the same.'
there's the thalidomide issue and I believe there were I think they were maybe doing studies or something where women were involved and obviously birth defects and horrible things happened and they sort of took women virtually off the table in terms of studying and so there's a long period of time where it was I think men were predominantly being studied and with subjects of yeah yeah we would just sort of assume that whatever is we see in the men we might see in the women
Recommendations
Products, supplements, and tools mentioned in the episode
3 items
Whiteboard hormone curve consultation for PMS patients
Practice
Attia describes drawing the complete 28-31 day hormone trajectory (FSH, LH, estradiol, progesterone, testosterone) for a patient in her living room as a transformative educational tool for understanding PMS.
The practice is not a product recommendation but a clinical habit: sitting down with a patient and actually mapping the hormonal arc across her full cycle, labeling each hormone, and specifically highlighting the day 22-28 progesterone drop and why it affects the central nervous system. The patient's reaction — 'I've always just thought I was kind of crazy' — illustrates the educational gap. Attia implies this should be standard practice for any woman presenting with luteal-phase mood symptoms.
Personal experience
Attia explicitly describes doing this personally in a patient's living room: 'I was sitting down with her in her living room actually drawing this out for her and explaining to her why she has PMS.'
I was sitting down with her in her living room actually drawing this out for her and explaining to her why she has PMS and let's highlight what's happening on about day 22 to 28 which is when you have this drop in progesterone
Read the actual Women's Health Initiative methodology before advising on HRT
Practice
Attia recommends that any clinician treating menopausal women actually read and understand WHI methodology and its limitations — rather than reflexively concluding 'no hormones ever.'
This is framed as a professional responsibility, not a product recommendation. The WHI studied a specific population (older women, mean age 63), using specific hormone formulations (conjugated equine estrogen + medroxyprogesterone acetate), and its findings are frequently generalized beyond their scope. Clinicians who dismiss HRT wholesale without understanding these limits are, in Attia's view, causing preventable harm to their patients via muscle loss, bone density decline, and unmanaged vasomotor symptoms.
without having ever even read a single study or tried to understand the limits and the methodologies of the Women's Health Initiative come to the conclusion well no woman should ever take hormones
Expand thyroid workup beyond TSH in post-partum women with 3-4 pregnancies
Practice
For women with persistent fatigue after three or four pregnancies who test normal on TSH, Attia recommends evaluating peripheral T4 metabolism specifically rather than dismissing the complaint.
Standard practice stops at TSH, which measures pituitary-thyroid feedback but not peripheral conversion of T4 to active T3. In Attia's clinical experience, women after multiple pregnancies frequently show altered peripheral metabolism that is missed by TSH-only screening. The treatment is relatively straightforward once the pattern is identified. He describes these patients as falling 'through the cracks' of conventional endocrinology.
empirically it is so overwhelming that I would be surprised if it's not described in the literature is there's something about multiple pregnancies and the HPA axis and women so I usually don't see it after a woman has had two kids but usually if a woman has had three or four kids the likelihood that her thyroid bounces back to normal seem is not that high
Lines worth pulling out — contrarian, specific, or perfectly phrased
5 items
for some women that central meaning in the in the brain that reduction that withdrawal of progesterone can create emotional lability and other things and it's like you're not crazy like that's like saying like someone who's depressed because they don't have enough serotonin is crazy
The cleanest clinical reframe of PMS: a neurochemical event, not a character flaw — and a direct validator for the many women who have been dismissed or told to tough it out.
when all three of those hormones are basically taken away in a period of two to three years I don't want to get too far on the soapbox but like definitely top 5 pet peeves are doctors that completely disregard menopausal perimenopausal and post menopausal symptoms and women and who without having ever even read a single study or tried to understand the limits and the methodologies of the Women's Health Initiative come to the conclusion well no woman should ever take hormones
Attia's most emphatic position in the episode — moral clarity that inadequate HRT education is causing preventable harm at scale.
the testosterone is about ten times higher than the estrogen hmm now the number never looks that way because testosterone is reported typically in nanograms per deciliter whereas the estrogen is reported usually in pika grams per milliliter
Exposes a widespread unit-reporting artifact that causes clinicians to systematically underestimate testosterone's dominance in female physiology — and therefore underestimate what menopause actually takes away.
you look at them and they have a normal TSH typically but but usually their peripheral metabolism of t4 is is very altered and and these are I think in some ways like kind of the easiest saves like you in a very short period of time you can make a patient feel a hell of a lot better and and they're just there they sort of fall through the cracks
The clinical tragedy of the post-partum thyroid pattern: trivially fixable but systematically missed by standard panels.
if you look at Alzheimer's disease and you look at the prevalence I think it's two out of every three cases are women and I have a hard time believing that that is purely an age issue
Challenges the comfortable explanation (longevity) for the sex gap in Alzheimer's — implying a biologically sex-specific mechanism that demands research.
Sign in to share feedback
Tell us if this brief hit the mark or missed it — feedback feeds back into the next iteration of the prompt.
Reading is free for everyone. A free account adds the personal layer: save protocols, follow experts, and see how the other experts weigh in on this same topic.
Educational summary of the cited expert source — not medical advice. Open the source recording linked above and consult a qualified physician before acting on any protocol.
